Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.
Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
The University of California Berkeley has sold a non-fungible token based on patent disclosures for Nobel Prize-winning cancer immunotherapies research at an online auction, netting approximately $54,360 from the sale.
Two former GlaxoSmithKline researchers do not have to pay restitution for stealing the drugmaker’s trade secrets, a Pennsylvania court has ruled.
A cannabis company has asked a district court to reconsider its summary judgment motion in a lawsuit over the trademark ‘Kiva’ in light of new evidence.
Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.
French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
Companies looking to enter the booming cannabis industry should “cast a wider net” when registering trademarks, according to a virtual panel discussion.
Talks over a COVID-19 vaccine waiver ended this week at the World Trade Organization in Geneva, with an agreement to work towards a text-based response to the plan.